FGFR Inhibitor AZD4547

DRUG3 trials

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmFGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene AmplificationFGFR2 Gene MutationFGFR3 Gene AmplificationFGFR3 Gene Mutation

Phase 2

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CompletedNCT02965378

SWOG Cancer Research NetworkFGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification +5

Start: 2014-10-31End: 2019-10-31Updated: 2021-05-27

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

CompletedNCT04439240

National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3

Start: 2016-05-31End: 2020-06-30Updated: 2021-06-29

Unknown Phase

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CompletedNCT02154490

SWOG Cancer Research NetworkRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Start: 2014-07-08End: 2022-04-15Updated: 2023-06-01

Cancer Research2022-06-15

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology2022-06-01

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer2021-08-0145 citations

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology2021-07-1596 citations

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

2020-10-2790 citations

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Cell Research2020-07-27298 citations

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology2020-05-201 citations

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

Journal of Clinical Oncology2019-05-208 citations

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

Journal of Clinical Oncology2018-05-202 citations

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

Journal of Clinical Oncology2017-05-2016 citations

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Genome Medicine2016-10-25275 citations

Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.

Journal of Clinical Oncology2016-05-20

FGFR Inhibitor AZD4547

Sponsors

Conditions

Phase 2

Unknown Phase

Related Papers